March 25, 2020 / 7:35 AM / 14 days ago

BRIEF-Lidds Says Analysis Of Tumors Confirms Depot Function Of NZ-Tlr9

March 25 (Reuters) - Lidds AB:

* REG-LIDDS ANNOUNCES POSITIVE PRECLINICAL DATA FOR NANOZOLID®-TLR9 AGONIST PROJECT

* LIDDS AB - IN VIVO EFFICACY IS AS GOOD AS WITH REPEATED INJECTIONS OF STANDARD TLR9 AGONIST

* LIDDS AB - PHARMACOKINETIC ANALYSIS OF TREATED TUMORS HAS CONFIRMED DEPOT FUNCTION OF NZ-TLR9.

* LIDDS AB - HAS PERFORMED PRECLINICAL STUDIES USING A TLR9 AGONIST FORMULATED WITH NANOZOLID® (NZ-TLR9) SHOWING THAT A SINGLE NZ-TLR9 INJECTION IS REDUCING TUMOR GROWTH AND IMPROVES SURVIVAL RATE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below